Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2024-12-23 Major Shareholding Noti…
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
Becoming a substantial holder 33 pages 1.5MB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 603' and references the Corporations Act 2001 Section 671B, which pertains to the notice of an initial substantial holder. It details the substantial shareholding of JPMorgan Chase & Co. and its affiliates in Mesoblast Ltd, including voting power, relevant interests, registered holders, and consideration paid for securities. The document includes detailed transaction data for the relevant period. This type of filing is a notification of a major shareholding or change in significant share ownership levels, which aligns with the definition of 'Major Shareholding Notification' (Code: MRQ). The document is not an annual report, earnings release, or any other financial report but a regulatory disclosure of shareholding. The length and detail confirm it is the actual notification, not just an announcement of a report. Therefore, the correct classification is MRQ with high confidence.
2024-12-23 English
AMENDMENT NO. 1 TO FORM F-3
Regulatory Filings
2024-12-23 English
6-K
Regulatory Filings
2024-12-23 English
6-K
Regulatory Filings
2024-12-20 English
6-K
Regulatory Filings
2024-12-20 English
Cleansing Notice 1 page 234.0KB
Regulatory Filings Classification · 95% confidence The document is a notice under Section 708A(5)(e) of the Corporations Act 2001 (Cth) regarding the issuance of shares without disclosure under Part 6D.2 of the Corporations Act. It is a formal regulatory announcement related to share issuance compliance and legal disclosure requirements. The document is short (1511 characters) and does not contain financial statements or detailed financial data. It is not an annual report, interim report, or earnings release. It is not a report publication announcement since it is a substantive notice itself. The content fits best under Regulatory Filings (RNS) as it is a compliance-related announcement that does not fit other specific categories like Share Issue/Capital Change (SHA) because it is a legal notice under the Corporations Act rather than a direct announcement of new share issuance terms or capital changes. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-12-19 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.